You are now leaving XTANDI.com
The website you are about to visit is not owned or controlled by Astellas. Astellas are not responsible for the information or services on this site.
NORTHBROOK, Ill., Aug. 16, 2018 /PRNewswire/ -- Astellas today announced that David Abbott has been promoted to national vice president Key Account Management (KAM). Abbott's previous role was senior director of Key Account Management for the company's Oncology franchise.
As National Vice President of KAM, Abbott will oversee teams who work with large healthcare organizations to provide educational resources and tools that help customers identify, educate and treat patients within therapeutic areas of interest to Astellas. Abbott joined Astellas in 2013.
"Astellas is deeply committed to delivering and creating value through products that serve our patients," said Percival Barretto-Ko, president, Astellas Americas. "I'm confident that David's deep experience, patient focus and track record at Astellas will position the company well as we build for the future."
Based in Massachusetts, Abbott brings more than 20 years of biopharma experience to his new role. Prior to joining Astellas, Abbott served as national access director at AVEO Oncology. He also held roles of increasing responsibility at Sanofi and Sanofi Genzyme, including regional sales manager for Hospital and Oncology, Oncology Access & Reimbursement account manager, and director of Multiple Sclerosis Payer and Channel Marketing.
Abbott holds a degree in Political Science from Providence College.
About Astellas
Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. For more information on Astellas, please visit our website at http://www.astellas.us/. You can also follow us on Twitter at @AstellasUS, Facebook at http://www.facebook.com/AstellasUS or LinkedIn at www.linkedin.com/company/astellas-pharma.
SOURCE Astellas
Get only the email alerts you want.
For media inquiries and reporter requests, please email us at corporate.communications@us.astellas.com.
Our communications team will respond to verified media requests within 24-48 hours as appropriate.
If you are not a reporter and need assistance, please visit our contact us page that includes information for patients, healthcare providers and researchers.
This website is intended for U.S. residents only. This website contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, or in different dosages. Nothing contained herein should be considered a solicitation, promotion or advertisement for any drug including those under development. Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider.
The site uses cookies to provide you with a more responsive and personalized service and to analyze site traffic. By using this site, you accept our use of cookies as described in our privacy policy. Please read our privacy policy for more information on the cookies we use, the processing of your personal data and how to delete or block the use of cookies.